Inomax

Nitric Oxide, the active ingredient in Inomax, is a vasodilator presented as a medical gas for endotracheopulmonary use. It is employed to treat neonatal hypoxic respiratory failure, pulmonary hypertension, and acute respiratory distress syndrome in patients requiring selective pulmonary vasodilation.

GNH USA supplies Inomax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Inomax acts as a selective pulmonary vasodilator, improving oxygenation in disorders with elevated pulmonary vascular resistance.

Neonatal hypoxic respiratory failure: improves oxygenation by reducing pulmonary vascular resistance. Pulmonary hypertension: lowers pulmonary arterial pressure and eases right‑ventricular workload. Acute respiratory distress syndrome: enhances ventilation‑perfusion matching and supports gas exchange.

Inomax may cause adverse reactions that require monitoring.

Common Side Effects: - Methemoglobinemia: elevated methemoglobin reducing oxygen delivery. - Increased nitrogen dioxide levels: airway irritation. - Transient systemic hypotension: mild drop in blood pressure.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in lungs. - Severe hypotension: marked drop in systemic blood pressure. - Bleeding complications: increased risk of hemorrhage in vulnerable patients.

Use of Inomax requires careful clinical oversight.

Monitor methemoglobin levels: perform regular blood tests during therapy. Avoid concurrent phosphodiesterase inhibitors: risk of excessive vasodilation. Use cautiously in hemolytic disease: potential for hemolysis. Limit exposure time: adhere to institutional protocols for duration. Store at ambient temperature: keep cylinder in original container, protect from heat and direct sunlight.

Inomax can interact with other agents that affect vascular tone or nitric oxide metabolism.

Major Interactions (Avoid): - Phosphodiesterase inhibitors: additive vasodilatory effect may cause severe hypotension. - Inhaled anesthetics (e.g., nitrous oxide): increased risk of methemoglobinemia.

Moderate Interactions (Monitor Closely): - Bronchodilators: may enhance pulmonary vasodilation. - Anticoagulants: monitor for bleeding tendencies. - Blood transfusions: can affect nitric oxide scavenging and hemoglobin levels.